New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
close
close
Send us Feedback
Inhibitex (INHX)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
SEC FILINGS
BALANCE
INCOME
CASH FLOW
INHX
»
Topics
»
Form 10-Q
This excerpt taken from the
INHX 10-Q
filed Aug 9, 2007.
Form 10-Q
(Mark One)
þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2007
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File
No. 0-50772
"Form 10-Q" elsewhere:
ACADIA Pharmaceuticals (ACAD)
AGENUS INC (AGEN)
ARIAD Pharmaceuticals (ARIA)
BioCryst Pharmaceuticals (BCRX)
Biopure (BPUR)
Corcept Therapeutics (CORT)
Curis (CRIS)
Cyclacel Pharmaceuticals (CYCC)
EXACT Sciences (EXAS)
GTC Biotherapeutics (GTCB)
IGI (IG)
Metabasis Therapeutics (MBRX)
Molecular Insight Pharmaceuticals (MIPI)
MediciNova (MNOV)
Neose Technologies (NTEC)
Osiris Therapeutics (OSIR)
Progenics Pharmaceuticals (PGNX)
Polydex Pharmaceuticals (POLXF)
Peregrine Pharmaceuticals (PPHM)
Savient Pharmaceuticals (SVNT)
AmpliPhi Biosciences Corp (TGEN)
Theravance (THRX)
Vical (VICL)
XenoPort (XNPT)
CORD BLOOD AMERICA (CBAI)
Bet you've never seen portfolio analytics like these.
Introducing
SigFig
— from the creators of
Take Tour